Skip to main content
2024 Guide to Patient Support Services

AAA PatientCONNECT

2024 PSS Guide

AAA PatientCONNECT

Advanced Accelerator Applications (AAA), a Novartis Company, offers the AAA PatientCONNECT program to deliver assistance to eligible patients who have been prescribed Pluvicto (Table).

AAA PatientCONNECT

Enrollment in AAA PatientCONNECT activates a continuum of support for your patients that may include benefits verification/prior authorization information, product ordering, reimbursement information, and financial assistance options.

AAA PatientCONNECT Copay Assistance Program

Co-pay savings are available for patients with private insurance. Please download the enrollment form at www.aaa patientconnect.com for additional eligibility criteria.

The Novartis Patient Assistance Foundation

The Novartis Patient Assistance Foundation (NPAF) is committed to providing access to Novartis medications for those most in need.

To enroll your patient in AAA PatientCONNECT, including the Copay Assistance Program or the Novartis Patient Assistance Foundation, complete the application online.

TABLE AAA Oncology Drug

Drug
Indication
Patient support program

Drug
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) injection
Indication
For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy
Patient support program